UK markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
8,040.00-101.00 (-1.24%)
At close: 4:29PM BST
Full screen
Previous close8,141.00
Open8,222.00
Bid8,066.00 x 0
Ask8,067.00 x 0
Day's range8,029.00 - 8,265.00
52-week range6,499.80 - 8,848.00
Volume1,586,348
Avg. volume3,280,355
Market cap124.55B
Beta (5Y monthly)0.19
PE ratio (TTM)38.67
EPS (TTM)207.90
Earnings date12 Nov 2021
Forward dividend & yield2.02 (2.49%)
Ex-dividend date12 Aug 2021
1y target estN/A
  • Globe Newswire

    Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

    MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021. In particular, the results of the interim analysis showed monalizumab in combination with durvalumab improved progression-free survival (PFS) and objective res

  • Business Wire

    IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer

    WILMINGTON, Del., September 17, 2021--Results from the large, randomized COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with IMFINZI® (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to IMFINZI alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).

  • Motley Fool

    2 Pharma Stocks You Can Buy and Hold for the Next Decade

    In the past 10 years, the pharmaceutical industry's performance has lagged well behind that of the broader market. The SPDR S&P Pharmaceutical Index ETF, an industry benchmark, is up by 107% in the past decade, less than half what the S&P 500 has returned in the same period. It could be that investors are worried about a complete overhaul of the entire healthcare industry, which has been the goal of several prominent U.S. politicians.